Kura Oncology, Inc.
Sr Mgr/Associate Director, FP&A
Kura Oncology, Inc., San Diego, California, United States, 92189
Senior Manager / Associate Director, FP&A Business Partner
Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
We are working to change the paradigm and improve the science of cancer treatment. We cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient‑focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to help make our vision a reality.
Essential Job Functions The Senior Manager / Associate Director, Financial Planning & Analysis (FP&A) will be a key member of the FP&A team, providing operational planning, analytical insights, and strategic financial support to help Kura achieve its commercial, operational and long‑term financial objectives.
Support and help lead the FP&A function, including long‑range planning, annual budgeting, rolling forecasts, and analysis of actual results versus plan.
Serve as the FP&A business partner for SG&A functions and selected R&D departments, identifying opportunities for efficiency, cost optimization, and process improvement.
Lead the preparation, analysis and presentation of financial results, forecasts and outlooks for supported functions on a quarterly and annual basis.
Develop a deep understanding of functional operations and resource requirements to effectively challenge assumptions, budgets and investment requests.
Provide timely, accurate and insightful financial analysis and business context to support operating and strategic decision‑making.
Critically review and evaluate annual and multi‑year budget submissions; documenting issues, communicating findings and partnering with stakeholders to resolve concerns.
Leverage financial systems and tools to analyze and synthesize large data sets into clear, summarized insights for business partners.
Contribute to ongoing improvements in FP&A processes, reporting and systems to enhance scalability and decision support.
Perform other duties as assigned.
Job Qualifications
Bachelor’s degree in Finance, Accounting, Economics or a related field.
5+ years of progressive experience in FP&A, corporate finance or related roles, preferably within a biotech or pharma organization.
Hands‑on experience with budgeting, forecasting, long‑range planning and variance analysis.
Strong planning, reporting and analytical skills with demonstrated business and systems proficiency.
Demonstrated ability to partner effectively with cross‑functional stakeholders and support business leaders with financial decision‑making.
Strong proficiency in financial modeling, forecasting and preparing external presentations; advanced Excel and PowerPoint skills; experience with financial planning software (e.g. Adaptive Insights, Hyperion) a plus.
Highly organized and detail‑oriented, with the ability to manage multiple priorities in a fast‑paced environment.
The base range for a Senior Manager is $165,000 – $187,000 and for an Associate Director is $176,000 – $192,000 per year. Individual pay may vary based on additional factors, including job‑related skills, experience, work location and relevant education or training. Kura’s compensation package also includes generous benefits, equity and participation in an annual target bonus.
Kura’s Values
We work as one for patients.
We are goal‑focused and deliver with excellence.
We are science‑driven courageous innovators.
We strive to bring out the best in each other and ourselves.
The Kura Package
Career advancement/development opportunities.
Competitive compensation package.
Bonus.
401(k) plus employer contributions.
Generous stock options.
ESPP plan.
20 days of PTO to start.
18 holidays (including Summer & Winter break).
Generous benefits package with a variety of plans and substantial employer match.
Paid paternity/maternity leave.
In‑office catered lunches.
Home office setup.
Lifestyle spending stipend.
Commuter stipend (Boston Office).
Regular employee social activities – happy hours, monthly birthday celebrations, Kura Koffee Talks, and more.
Company Overview Kura Oncology is a clinical‑stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small‑molecule drug candidates targeting cancer signaling pathways. Ziftomenib, a once‑daily oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory NPM1‑mutant acute myeloid leukemia (AML).
In November 2024 Kura entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize Ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration‑directed trial of Ziftomenib in R/R NPM1‑mutant AML has been completed, and in the second quarter of 2025 the companies announced FDA acceptance of a New Drug Application for Ziftomenib for adult patients with R/R NPM1‑mutant AML with a Prescription Drug User Fee Act target action date of November 30 2025. Kura is also conducting clinical trials evaluating Ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1‑mutant and KMT2A‑rearranged AML. KO‑2806, our next‑generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose‑escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA‑dependent head and neck squamous cell carcinoma.
For additional information, please visit https://www.kuraoncology.com and follow us on X and LinkedIn.
We are committed to creating a diverse environment and are proud to be an equal‑opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age or veteran status.
If you are a California resident, please see the attached Privacy Notice CA Privacy Notice.
#J-18808-Ljbffr
We are working to change the paradigm and improve the science of cancer treatment. We cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient‑focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to help make our vision a reality.
Essential Job Functions The Senior Manager / Associate Director, Financial Planning & Analysis (FP&A) will be a key member of the FP&A team, providing operational planning, analytical insights, and strategic financial support to help Kura achieve its commercial, operational and long‑term financial objectives.
Support and help lead the FP&A function, including long‑range planning, annual budgeting, rolling forecasts, and analysis of actual results versus plan.
Serve as the FP&A business partner for SG&A functions and selected R&D departments, identifying opportunities for efficiency, cost optimization, and process improvement.
Lead the preparation, analysis and presentation of financial results, forecasts and outlooks for supported functions on a quarterly and annual basis.
Develop a deep understanding of functional operations and resource requirements to effectively challenge assumptions, budgets and investment requests.
Provide timely, accurate and insightful financial analysis and business context to support operating and strategic decision‑making.
Critically review and evaluate annual and multi‑year budget submissions; documenting issues, communicating findings and partnering with stakeholders to resolve concerns.
Leverage financial systems and tools to analyze and synthesize large data sets into clear, summarized insights for business partners.
Contribute to ongoing improvements in FP&A processes, reporting and systems to enhance scalability and decision support.
Perform other duties as assigned.
Job Qualifications
Bachelor’s degree in Finance, Accounting, Economics or a related field.
5+ years of progressive experience in FP&A, corporate finance or related roles, preferably within a biotech or pharma organization.
Hands‑on experience with budgeting, forecasting, long‑range planning and variance analysis.
Strong planning, reporting and analytical skills with demonstrated business and systems proficiency.
Demonstrated ability to partner effectively with cross‑functional stakeholders and support business leaders with financial decision‑making.
Strong proficiency in financial modeling, forecasting and preparing external presentations; advanced Excel and PowerPoint skills; experience with financial planning software (e.g. Adaptive Insights, Hyperion) a plus.
Highly organized and detail‑oriented, with the ability to manage multiple priorities in a fast‑paced environment.
The base range for a Senior Manager is $165,000 – $187,000 and for an Associate Director is $176,000 – $192,000 per year. Individual pay may vary based on additional factors, including job‑related skills, experience, work location and relevant education or training. Kura’s compensation package also includes generous benefits, equity and participation in an annual target bonus.
Kura’s Values
We work as one for patients.
We are goal‑focused and deliver with excellence.
We are science‑driven courageous innovators.
We strive to bring out the best in each other and ourselves.
The Kura Package
Career advancement/development opportunities.
Competitive compensation package.
Bonus.
401(k) plus employer contributions.
Generous stock options.
ESPP plan.
20 days of PTO to start.
18 holidays (including Summer & Winter break).
Generous benefits package with a variety of plans and substantial employer match.
Paid paternity/maternity leave.
In‑office catered lunches.
Home office setup.
Lifestyle spending stipend.
Commuter stipend (Boston Office).
Regular employee social activities – happy hours, monthly birthday celebrations, Kura Koffee Talks, and more.
Company Overview Kura Oncology is a clinical‑stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small‑molecule drug candidates targeting cancer signaling pathways. Ziftomenib, a once‑daily oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory NPM1‑mutant acute myeloid leukemia (AML).
In November 2024 Kura entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize Ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration‑directed trial of Ziftomenib in R/R NPM1‑mutant AML has been completed, and in the second quarter of 2025 the companies announced FDA acceptance of a New Drug Application for Ziftomenib for adult patients with R/R NPM1‑mutant AML with a Prescription Drug User Fee Act target action date of November 30 2025. Kura is also conducting clinical trials evaluating Ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1‑mutant and KMT2A‑rearranged AML. KO‑2806, our next‑generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose‑escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA‑dependent head and neck squamous cell carcinoma.
For additional information, please visit https://www.kuraoncology.com and follow us on X and LinkedIn.
We are committed to creating a diverse environment and are proud to be an equal‑opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age or veteran status.
If you are a California resident, please see the attached Privacy Notice CA Privacy Notice.
#J-18808-Ljbffr